This week: Lilly’s Foundayo pill moved closer to EU approval, Novo shared new CagriSema data for women, a compounded tirzepatide product was recalled, and ACOG released GLP-1 pregnancy guidance.
The American College of Obstetricians and Gynecologists released long-awaited guidance to help ob-gyns counsel patients about GLP-1 medications before, during and after pregnancy.
A North Carolina compounding pharmacy voluntarily recalled 22 lots of compounded tirzepatide because it couldn’t assure the vials were sterile, and here are the details from the FDA’s record.
A new EY-Parthenon survey finds that 54% of U.S. GLP-1 users now take the medication mainly for weight management, and their grocery carts and closets are changing too.
New after-the-fact analyses of Novo Nordisk’s REDEFINE 1 trial found women on the experimental shot CagriSema lost about 25% of their body weight on average, with strong results across menopause stages.
Europe’s drug committee recommended EU approval of Eli Lilly’s once-daily GLP-1 pill Foundayo, leaving one final sign-off before it can reach European pharmacies.
Tideflock has no paywalls, no ads, and will never sell your health data. Here’s why we built a free GLP-1 tracker and how a tip jar keeps it going.
Starting a GLP-1? Here’s what to track in your first month, from doses and injection sites to side effects, protein and water, and why each one matters.